Manner Carrie Eglinton Buys 22,022 Shares of OraSure Technologies (NASDAQ:OSUR) Stock

OraSure Technologies, Inc. (NASDAQ:OSUR) CEO Manner Carrie Eglinton acquired 22,022 shares of the company’s stock in a transaction that occurred on Friday, March 13th. The stock was purchased at an average cost of $3.00 per share, for a total transaction of $66,066.00. Following the purchase, the chief executive officer owned 2,158,574 shares of the company’s stock, valued at $6,475,722. This represents a 1.03% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

OraSure Technologies Stock Down 4.8%

Shares of NASDAQ OSUR opened at $2.98 on Wednesday. The business has a fifty day simple moving average of $2.84 and a two-hundred day simple moving average of $2.79. The firm has a market cap of $206.00 million, a PE ratio of -3.20 and a beta of 0.88. OraSure Technologies, Inc. has a twelve month low of $2.08 and a twelve month high of $4.22.

OraSure Technologies (NASDAQ:OSUR) last posted its quarterly earnings results on Wednesday, February 25th. The medical instruments supplier reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.02). The firm had revenue of $26.76 million for the quarter, compared to the consensus estimate of $26.44 million. OraSure Technologies had a negative return on equity of 16.45% and a negative net margin of 59.76%. On average, research analysts expect that OraSure Technologies, Inc. will post -0.08 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in OSUR. Altai Capital Management L.P. boosted its position in OraSure Technologies by 73.4% during the third quarter. Altai Capital Management L.P. now owns 3,748,836 shares of the medical instruments supplier’s stock valued at $12,034,000 after purchasing an additional 1,586,488 shares in the last quarter. Private Management Group Inc. raised its holdings in OraSure Technologies by 23.6% in the second quarter. Private Management Group Inc. now owns 5,461,440 shares of the medical instruments supplier’s stock worth $16,384,000 after purchasing an additional 1,044,213 shares in the last quarter. Systematic Financial Management LP raised its holdings in OraSure Technologies by 35.3% in the second quarter. Systematic Financial Management LP now owns 2,229,076 shares of the medical instruments supplier’s stock worth $6,687,000 after purchasing an additional 581,926 shares in the last quarter. Cannell Capital LLC lifted its position in shares of OraSure Technologies by 12.6% during the third quarter. Cannell Capital LLC now owns 2,099,815 shares of the medical instruments supplier’s stock valued at $6,740,000 after buying an additional 234,826 shares during the last quarter. Finally, Intech Investment Management LLC lifted its position in shares of OraSure Technologies by 37.4% during the second quarter. Intech Investment Management LLC now owns 60,620 shares of the medical instruments supplier’s stock valued at $182,000 after buying an additional 16,506 shares during the last quarter. 93.50% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (d)” rating on shares of OraSure Technologies in a research report on Thursday, January 22nd. Two research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Reduce” and an average price target of $3.00.

Key OraSure Technologies News

Here are the key news stories impacting OraSure Technologies this week:

• Positive Sentiment: Insiders (CEO Carrie Eglinton and CFO Kenneth McGrath) purchased stock on March 13, increasing their holdings — a signal of management confidence that can support the share price. CEO Form 4 CFO Form 4
• Neutral Sentiment: OraSure issued a public rebuttal to Altai Capital, emphasizing operational progress, upcoming regulatory/commercial milestones and ongoing engagement — the company says it has rejected settlement offers and will not cede to a rushed sale process; this is a standard defensive response that reduces uncertainty but doesn’t resolve the activist’s demands. Company Statement
• Negative Sentiment: Activist Altai Capital (≈5% owner) delivered a detailed letter pressing OraSure to explore a sale and seeking board seats, saying the company could fetch materially higher value — this raises near-term takeover speculation, governance fight risk and potential for a forced sale process, which is increasing selling pressure and volatility. Reuters: Altai Presses OraSure BusinessWire: Altai Letter

OraSure Technologies Company Profile

OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.

The company’s flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.